Randomised, double-blind, placebo-controlled study to assess long-term effect of dupilumab on prevention of lung function decline (LFD) in patients with uncontrolled moderate-to-severe asthma: ATLAS trial
L. De Prado Gomez (Reading, United Kingdom), I. Pavord (Oxford, United Kingdom), W. Busse (WI, United States), C. Brightling (Leicester, United Kingdom), M. Wechsler (Grosshansdorf, Germany), K. Rabe (Keil, United Kingdom), M. Zhang (NJ, United States), J. Xing (NJ, United States), J. Jacob-Nara (NJ, United States), P. J Rowe (NJ, United States)
Source: International Congress 2022 – Exhaled/blood biomarkers and lung function testing in chronic airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. De Prado Gomez (Reading, United Kingdom), I. Pavord (Oxford, United Kingdom), W. Busse (WI, United States), C. Brightling (Leicester, United Kingdom), M. Wechsler (Grosshansdorf, Germany), K. Rabe (Keil, United Kingdom), M. Zhang (NJ, United States), J. Xing (NJ, United States), J. Jacob-Nara (NJ, United States), P. J Rowe (NJ, United States). Randomised, double-blind, placebo-controlled study to assess long-term effect of dupilumab on prevention of lung function decline (LFD) in patients with uncontrolled moderate-to-severe asthma: ATLAS trial. 3191
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|